Emerge Weight Loss vs LillyDirect Foundayo
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Emerge Weight Loss
Best for patients committed to tirzepatide as their drug of choiceStarting at $299/mo
LillyDirect Foundayo
Best for patients with commercial insurance who want the cheapest legal brand-name GLP-1Starting at $25/mo
Side-by-Side Comparison
| Feature | Emerge Weight Loss | LillyDirect Foundayo |
|---|---|---|
| Overall Score | 7.6/10 | ✓8.5/10 |
| Starting Price | $299/mo | ✓$25/mo |
| Customer Rating | — | — |
| Features | 4 features | ✓5 features |
| States Available | 50 | ✓51 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Emerge Weight Loss
Pros
- ✓Tirzepatide-focused (largest effect-size compounded GLP-1)
- ✓Wide dose range available
- ✓Physician-supervised telemedicine model
Cons
- ✗No semaglutide option — limits flexibility if tirzepatide tolerability is poor
- ✗Less brand recognition than Henry Meds, Mochi, or SkinnyRx
LillyDirect Foundayo
Pros
- ✓Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- ✓Direct from manufacturer — no compounding, no third-party reseller
- ✓Daily oral pill, no injections, no refrigeration
- ✓Available in all 50 states
Cons
- ✗Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- ✗Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- ✗$25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- ✗Strict empty-stomach 30-minute window may be hard for some patients to follow
Our Verdict
LillyDirect Foundayo edges out Emerge Weight Loss with a higher overall score of 8.5/10 and is particularly strong for patients with commercial insurance who want the cheapest legal brand-name GLP-1. Emerge Weight Loss remains a solid alternative, especially if you're looking for patients committed to tirzepatide as their drug of choice.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.